DEMO

Log In | Sign Up



Revvity

Selected Articles

2025-08-13
ETF Daily News
Charles Schwab Investment Management Inc. Boosts Stake in Revvity Inc. (NYSE:RVTY)
2025-08-07
GlobeNewswire
Allergy Diagnostics and Treatments Market to Reach $96.4 Billion by 2030
2025-08-07
PR Newswire UK
Autoimmunity Diagnostics Market worth US$8.98 billion by 2031 with 8.3% CAGR | MarketsandMarkets™
2025-08-06
ETF Daily News
Brokerages Set Revvity Inc. (NYSE:RVTY) PT at $120.07
2025-08-05
GlobeNewswire
Residual DNA Testing Global Market Forecast to 2030 | Novel Modalities, Emerging Markets Growth, Continuous Processing Integration, and Rising CRO/CDMO Outsourcing
2025-08-03
ETF Daily News
Revvity (NYSE:RVTY) Rating Lowered to "Hold" at Wall Street Zen
2025-08-01
ETF Daily News
Revvity's (RVTY) Outperform Rating Reiterated at Raymond James Financial
2025-08-01
ETF Daily News
Leerink Partnrs Weighs in on Revvity FY2025 Earnings
2025-08-01
ETF Daily News
Leerink Partnrs Estimates Revvity's Q3 Earnings (NYSE:RVTY)
2025-07-30
Biztoc.com
Revvity price target lowered to $110 from $120 at Stifel

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts. US7140461093 www.revvity.com